Bactrim Dosing and Usage Guidelines

Standard Adult Dosing

The Infectious Diseases Society of America recommends 1-2 double-strength tablets twice daily for skin and soft tissue infections, with a duration of typically 7 days based on clinical response, which is an AII-level recommendation 1, 2

For purulent cellulitis where MRSA is suspected, the Infectious Diseases Society of America recommends Bactrim, which has poor activity against beta-hemolytic streptococci, so it should not be used alone for non-purulent cellulitis where streptococci are likely pathogens 1, 2
The recommended dose for severe infections requiring IV administration, such as CNS infections or severe bacteremia, is 5 mg/kg/dose (based on trimethoprim) IV every 8-12 hours, which is a BIII/CIII recommendation for MRSA CNS infections 3
For complicated infections requiring parenteral therapy, the recommended dose is 8-12 mg/kg/day (based on trimethoprim component) divided into 4 doses IV 2

Bactrim is contraindicated in the third trimester of pregnancy due to kernicterus risk and is also contraindicated in nursing mothers 1, 4
The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, advises avoiding Bactrim in patients with sulfa allergies 4
The Infectious Diseases Society of America recommends against using Bactrim as monotherapy for mixed aerobic-anaerobic wound infections, as it lacks anaerobic coverage and requires combination therapy 2

The American Family Physician recommends a prophylactic dose of one DS tablet daily for PCP prophylaxis in immunocompromised patients, while an alternative regimen of one DS tablet three times weekly on consecutive days provides equivalent protection with potentially fewer side effects, as supported by the MMWR Recommendations and Reports 5, 6

Severe infections requiring parenteral therapy: administer IV trimethoprim‑sulfamethoxazole at 8–12 mg/kg/day (based on the trimethoprim component), divided into four equal doses, each infused over 1 hour. (MMWR Recommendations and Reports, 2004) 7

Hospitalized patients with severe infections (e.g., pyelonephritis, Pneumocystis pneumonia, severe bacteremia) should receive IV trimethoprim‑sulfamethoxazole; oral therapy is reserved for situations where the parenteral route is not feasible. (MMWR Recommendations and Reports, 2004; Clinical Infectious Diseases, 2011) 7, 8

Post‑acute pneumonitis switch: after clinical resolution of acute pneumonitis, patients may transition from IV to oral trimethoprim‑sulfamethoxazole using the same total daily dose to complete the prescribed course. (MMWR Recommendations and Reports, 2004) 7
Criteria for safe IV‑to‑oral conversion: the switch is appropriate for patients with mild‑to‑moderate disease who do not have malabsorption or diarrhea. (MMWR Recommendations and Reports, 2004) 7